07.08.25 -- A Psychedelic Path To CDMO Selection?

20-minute capacity and capabilities quick-looks, 20+ brand new CDMO presenters to evaluate for best-fit this quarter – and a (virtual) commitment of less than 20 percent of your day? We're confident you don't need 20/20 vision to see the value in this! Join us for Outsourced Pharma's July Partner Week – including sessions in Cell & Gene Therapy, Analytical Services, and Fill/Finish among others. Registration, on-demand access, and interactive Q&A are free.

Ensure the success of your tech transfer by addressing these key challenges and optimizing your processes for seamless scalability and compliance.

Plan early and align research, development, and commercial priorities to ensure a seamless transition from clinical development to scalable, cost-efficient commercialization.

Tariffs, geopolitical gyrations, (pending) laws such as the BIOSECURE Act; all affect your outsourcing optionality and decision-making. Our panel of internationally savvy biopharma executives provide some guiding insights.

To guarantee success, learn why it is crucial to partner with a CRO that can navigate the challenges of viral vector development and testing.

Observe why partnering with a U.S.-based company that owns its manufacturing assets allows for direct oversight of product quality and supply reliability.

Explore an increasingly popular vector for gene therapy applications, but challenges related to process and analytical development often require significant expertise.

This study evaluates the performance and productivity of VintaProcess in addressing the persistent manufacturing challenges in AAV gene therapy production.

Learn more about the leading oncolytic viruses, the leading cell lines, and how to strategize your oncolytic virus production plan.

Examine how expert formulation and analytical support facilitate the development of stable, injectable therapies across various delivery routes and molecular types.

Consider the difference a dedicated, expert project management team can make in ensuring the success and smooth execution of your cell therapy programs.

Watch as Senior Key Account Manager Dr. Jürgen Lübbehusen highlights our overall fill-finish capabilities and capacities, with a focus on our ability to help meet your complex needs.

Review why this cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade.

Witness how our LentiPeak™ platform can help you reach your next milestone faster. Our proprietary lentiviral vector platform offers a serum-free, transient transfection, HEK293-based process.

Whether your program requires research-grade, high-quality, or GMP-grade pDNA, we provide manufacturing solutions backed by robust quality control, regulatory expertise, and full traceability.